scholarly journals Endovascular transarterial embolization of cerebral arteriovenous malformation with ethylene-vinyl alcohol copolymer

2014 ◽  
Vol 37 (v1supplement) ◽  
pp. 1
Author(s):  
Lee A. Tan ◽  
Andrew K. Johnson ◽  
Kiffon M. Keigher ◽  
Roham Moftakhar ◽  
Demetrius K. Lopes

Cerebral arteriovenous malformations (AVMs) have an estimated 2–4% annual risk of hemorrhage. Treatment options for AVMs include microsurgical resection, stereotactic radiosurgery, and endovascular embolization. As endovascular technology and techniques continue to advance and mature, endovascular embolization is becoming an increasingly vital component of AVM treatment not only as a presurgical treatment to reduce microsurgical risks, but also as a stand-alone curative method in some cases. This case illustrates the successful and curative transarterial embolization of a right frontal AVM in a 17-year-old boy with ethylene-vinyl alcohol copolymer (Onyx).The video can be found here: http://youtu.be/L4hE1MvCZCY.

2013 ◽  
Vol 36 (5) ◽  
pp. 1288-1295 ◽  
Author(s):  
René Müller-Wille ◽  
Walter A. Wohlgemuth ◽  
Peter Heiss ◽  
Philipp Wiggermann ◽  
Oliver Güntner ◽  
...  

2012 ◽  
Vol 46 (3) ◽  
pp. 251-257 ◽  
Author(s):  
Kamal Massis ◽  
William G. Carson ◽  
Alexandra Rozas ◽  
Vishal Patel ◽  
Bruce Zwiebel

We report our single-center experience in treating 101 type II endoleaks with ethylene-vinyl-alcohol copolymer (EVOH, Onyx). In all, 65 endoleaks were embolized transarterially, and 36 were treated through a translumbar approach. Since the first transarterial embolization, when we began attempts to treat all patients initially via common femoral access, 58 (65.9%) of 88 patients were successfully embolized transarterially. All endoleaks in the translumbar group were successfully treated. At a median follow-up length of 15 weeks, a decrease or stabilization in aneurysm size was observed in 39 (73.6%) of the 53 endoleaks that had adequate follow-up computed tomography imaging. The overall residual endoleak rate was 34.0%. There was no difference in efficacy when comparing transarterial and translumbar approaches. We demonstrate that in most cases, transarterial access of the endoleak nidus is feasible, and controlled embolization is possible using EVOH. Furthermore, EVOH appears effective in long-term stabilization of aneurysm size and in preventing residual endoleaks.


2016 ◽  
Vol 6 (3) ◽  
pp. 323-327 ◽  
Author(s):  
Olivier Chevallier ◽  
Sophie Gehin ◽  
Alain Foahom-Kamwa ◽  
Pierre Pottecher ◽  
Sylvain Favelier ◽  
...  

VASA ◽  
2020 ◽  
Vol 49 (6) ◽  
pp. 483-491
Author(s):  
Anna-Leonie Menges ◽  
Matthias Trenner ◽  
Oksana Radu ◽  
Daisy Beddoe ◽  
Michael Kallmayer ◽  
...  

Summary: Background: Type II endoleak (T2EL) after endovascular aortic repair is associated with AAA sac enlargements in up to 25%, reduction of attachment zones and rarely with aortic rupture. Indications for therapy and efficacy of interventions of T2EL are not clearly established. Transarterial embolization with application of ethylene-vinyl alcohol copolymer has been described with varying outcomes. Aim of this study is to evaluate durability of OnyxTM embolization (OE) in T2EL in a consecutive series at a single tertiary vascular center. Patients and methods: Demographic data, technical success, pre- and postoperative aneurysm growth, morbidity, mortality and reintervention rates during hospital stay as well as in follow up were recorded in patients treated with OE for T2EL between 01/2015 and 12/2017. The primary endpoint was defined as persistence or reoccurrence of T2EL (durability of OE). Results: In total 15 patients (78 ± 6 years, 13 men) were treated with OE because of sac enlargement (average growth of 12 ± 8%, n = 12), persistent bleeding after AAA rupture (n = 2) or persistent T2EL with stable but large aneurysm diameter (n = 1). Mean length of stay was 8 ± 11 days. Technical success was 93.3% (n = 14). Inhospital-morbidity was 26.7%, in-hospital- and 1-year-mortality rate were 6.6% (n = 1) and 20.0% (n = 3). T2EL persisted in 20.0% (n = 3) despite of OE. Re-EL-II occurred after 40 (30–114) days in 33.3% (n = 5). Reintervention rate was 13.3% (n = 2, at day 48 and 319). Altogether clinical success with stable aneurysm diameter was achieved in 80.0% (n = 12), but durable elimination of EL was only achieved in 46.7% of patients (n = 7). Conclusions: OE is technically possible in more than 90% of patients but might be associated with severe complications. Durability of this treatment is low, since T2EL persist or reoccur in more than 50% of all patients. OE of T2EL should be reserved for few selected cases.


Sign in / Sign up

Export Citation Format

Share Document